Sapience Therapeutics, Inc.’s Post

🚨New Webinar Alert: Join Champions for our upcoming webinar 🚨 How to Design a Successful 3D Tumor Model Co-Culture Study Thursday September 5th, 2024 4pm CEST ◾10am EST ◾7am PST Save your spot: https://hubs.li/Q02LJyhH0 Join us for an insightful webinar with our immuno-oncology expert Dr. Mara Gilardi. This session will guide you through different aspects of designing an effective ex vivo 3D tumor model co-culture studies, focusing on model selection, donor choice, optimizing tumor-to-immune cell ratios, selecting controls, and choosing key readouts. Learn how to elevate your research with advanced 3D tumor models for more impactful oncology studies. #ImmunoOncology #tumorgraft3d #organoid #3dtumormodel #exvivo #CancerTreatment #OncologyInnovation #ImmunoTherapeutics #CancerTreatment ##CancerImmunotherapy #organoids #Coculture

If you missed our webinar, A New Frontier in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Biomarker Testing, you can view it with the link below. The webinar explores the role cfHPV-DNA plays in cancer prognosis, and what barriers biopharma companies face in incorporating cfHPV-DNA into their clinical trial design. The speakers discuss how pharma manufacturers, HCPs and patients can collaborate to help overcome these barriers. #HPV #CancerResearch https://hubs.la/Q02kBkYH0

AKT, also known as Protein Kinase B (PKB), is a crucial target in cancer therapy. The AKT Pathway (or PI3K-Akt Pathway) promotes cell survival and growth in response to extracellular signals. SignalChem Biotech, now part of Sino Biological, Inc., offers an extensive range of AKT kinases for oncology research. Discover how our kinase enzyme products can help advance your research! Explore More: https://ow.ly/8b9Q50SNGfn #AKTPathway #CellSignaling #ProteinKinases

In case you missed our webinar, A New Frontier in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Biomarker Testing, you can view it with the link below. The webinar explores the role cfHPV-DNA plays in cancer prognosis, and what barriers biopharma companies face in incorporating cfHPV-DNA into their clinical trial design. The speakers discuss how pharma manufacturers, HCPs and patients can collaborate to help overcome these barriers. #HPV #CancerResearch https://hubs.la/Q02kM-g50

#AACR24, here we come!   We can’t wait to share with you the latest from our #DrugDiscovery labs next Monday. Here’s a preview 👇    💡 Abstract 2945 / 20: Find out how our #FunctionalGenomicsCentre’s teams are reducing the experimental scale of #CRISPR screens by 50%.     💡 Abstract 3333 / 21: Learn about ASTX295, a potent inhibitor of the MDM2-p53 interaction currently under clinical investigation.     Are you presenting at #AACR24? Let us know where and when in the comments.    #OnMyHorizon #Oncology Steve Wedge, David Walter, Astex Pharmaceuticals and American Association for Cancer Research

Clinical trials benefit patients and divert specialty drug costs, but barriers to enrollment include access, costs and coverage, and delays from tissue genomic tumor profiling. Our study shows that patients with non–small cell lung cancer enrolling in clinical trials following liquid biopsy had improved survival without increasing costs compared with matched controls. Specialty drug management should include coverage for testing likely to guide the appropriate use of therapies, which improves survival and drives clinical trial enrollment, also improving survival. #lungcancer #lcsm https://lnkd.in/e6vAQmcM

In addition to being asked, “Why CD24?” – I also get asked, “How is your lead drug candidate, PHST001, differentiated?” Due to the complex glycosylation patterns on CD24, not all antibodies against this target are created equal. We have engineered PHST001 to interact with all glyco-variants of CD24, which enables potent activity. And our preclinical data show that we are on the right track. Macrophage checkpoint inhibitors hold tremendous promise, and I believe that PHS001 can strike the right balance of safety and efficacy that is crucial to success. Thanks @PharmaShots for the opportunity to discuss the potential impact of PHST001, how it works, and the impact it could make on the field of cancer immunotherapy.

🎯 Out of the lab and into patients: targeting APE1/Ref-1 I had the privilege of speaking to Dr Mark R. Kelley, Associate Director of Basic Science at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, and Betty and Earl Herr Professor in Pediatric Oncology Research, prior to his talk at American Association of Pharmaceutical Scientists (AAPS) | @aapscomms PharmSci360 in 2024. He elucidates what makes APE1/Ref-1 a promising target for cancer therapy, as well as promising preclinical data which indicates that other diseases could be addressed. Click on the link in the comments to read more! 👇 #cancer #preclinical #AAPS #PharmSci360

Exciting news! Our Business Development team is in Charlotte, North Carolina this week end to attend the AACR special conference on bladder cancer. If you're attending as well, be sure to stop by our booth to learn about how our cutting-edge #MIBC and #NMIBC models for preclinical oncology drug development. See you there! Discover more https://hubs.ly/Q02xFVXb0 #AACR2024 #BladderCancer #OncologyResearch #PreclinicalDrugDevelopment.